TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2897260
Drug: GHRH administration
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH administration in untreated control women
Study: 26012780
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with Staphylococcus epidermidis applied to the face twice per week for four weeks
Study: 24265159
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of MTX/6MP
Study: 24265159
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of MTX/6MP
Study: 21750293
Drug: BAL-directed therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL-directed therapy (n = 84)
Study: 21750293
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 86)
Study: 15041599
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus methylprednisolone 10 microg plus 40 mg
Study: 11149478
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1 g daily)
Study: 30987432
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 mg 3 times/d and hydration)
Study: 29696915
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Adalat 30 mg at 7 am daily for 6 weeks)
Study: 29696915
Drug: No.1 acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No.1 acupuncture group (acupuncture technique for activating blood circulation, eliminating wind and regulating the liver and spleen, in addition to medication)
Study: 29696915
Drug: No.2 acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No.2 acupuncture group (additional acupuncture at Fengchi (GB 20) and Neck‐Jiaji (EX‐B 2) on top of No.1 acupuncture group treatment)
Study: 12145715
Drug: Mupirocin nasal
Normalized name: mupirocin Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin nasal ointment applied twice daily from admission to surgery
Study: 12145715
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal ointment applied twice daily from admission to surgery
Study: 12145715
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal ointment
Study: 9990598
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy (i.v. procainamide)
Study: 8520806
Drug: Diclofenac dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac dispersible 46.5 mg (equivalent to 50 mg of diclofenac sodium)
Study: 2315431
Drug: Sibutramine HCl
Normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine HCl (15 mg twice daily)
Study: 2315431
Drug: Sibutramine HCl
Normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine HCl (single dose of 12.5 or 50 mg)
Study: 2315431
Drug: Sibutramine HCl
Normalized name: SIBUTRAMINE HCL 5MG CAP
DrugBank: Sibutramine (DB01105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sibutramine HCl (5‐20 mg once daily)
Study: 6968220
Drug: Indometacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (200 mg daily)
Study: 6968220
Drug: Acemetacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (200 mg daily)
Study: 6968220
Drug: Acemetacin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (240 mg daily)
Study: 21840055
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (specific statins not detailed)
Study: 21840055
Drug: Nonadherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadherence to medication
Study: 21840055
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about medicines (assessed using BMQ-G)
Study: 11878726
Drug: Ropivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 150 mg (7.5 mg ml(‐1))
Study: 11878726
Drug: Ropivacaine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 100 mg (5 mg ml(‐1))
Study: 11878726
Drug: Ropivacaine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 200 mg (10 mg ml(‐1))
Study: 11878726
Drug: Bupivacaine 100
Normalized name: BUPivacaine 100 mg parenteral implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 100 mg (5 mg ml(‐1))
Study: 2744356
Drug: Pentagastrin injection
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentagastrin injection
Study: 333606
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and intraoperative antibiotics
Study: 30904875
Drug: Pterygopalatine ganglion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pterygopalatine ganglion pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds
Study: 30904875
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block (NB) treatment with a mixture of steroids and local anaesthetics
Study: 20499024
Drug: Combination (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (500 mg vitamin C and 200 mg Tocovid)
Study: 20499024
Drug: Tocotrienol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol (200 mg)
Study: 1754635
Drug: ritanserin (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritanserin (5-10 mg)
Study: 6923655
Drug: Calcium heparin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin, 5000 IU s.c. every 8 hr for 7 days, first administration 2 hr before surgery
Study: 6709383
Drug: Imaginal strategy
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imaginal strategy treatment (response group) - trained to imagine pleasant scenes including muscular relaxation and deep breathing.
Study: 6709383
Drug: Imaginal strategy
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imaginal strategy treatment (stimulus group) - trained to imagine scenes with many stimulus details.
Study: 31852846
Drug: RN168 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RN168 1 mg/kg every other week (Q2wk)
Study: 31852846
Drug: RN168 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RN168 3 mg/kg every other week (Q2wk)
Study: 31852846
Drug: RN168 higher
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RN168 higher doses (not specified)
Study: 26863596
Drug: Aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic acid photodynamic therapy (ALA‐PDT)
Study: 26863596
Drug: Vehicle photodynamic
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle photodynamic therapy (VEH‐PDT)
Study: 24997559
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg for participants ≥18 years, 50 mg for those <18 years) and Lansoprazole (60 mg for participants ≥18 years, 30 mg for those <18 years)
Study: 20139792
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily activity counts
Study: 20139792
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily minutes of moderate to vigorous physical activity (MVPA)
Study: 17932823
Drug: 4% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% chlorhexidine solution
Study: 3286393
Drug: Ritodrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine infusion
Study: 1861962
Drug: Duraphat (2.26%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duraphat (2.26% fluoride), n = 206, six-monthly applications
Study: 1861962
Drug: Carex (1.80%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carex (1.80% fluoride), n = 189, six-monthly applications
Study: 29846719
Drug: sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucroferric oxyhydroxide 1.0-3.0 g/day
Study: 29846719
Drug: sevelamer 2.4-14.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: sevelamer 2.4-14.4 g/day
Study: 25667293
Drug: 10% Urea-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Urea-based cream (UBC) plus best supportive care (BSC)
Study: 19765131
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 ml diluted in physiologic saline) given as intravenous infusion once daily for 10 days
Study: 19765131
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) given as intravenous infusion once daily for 10 days
Study: 15570253
Drug: GM‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF plus G‐CSF
Study: 15570253
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of G‐CSF followed by GM‐CSF 6 days later
Study: 11148742
Drug: Alpha blocker-finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha blocker-finasteride combination therapy
Study: 10323611
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (bacitracin ointment applied 2-3 times daily)
Study: 6750206
Drug: Alternate-day steroids
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day steroids (ADS)
Study: 6750206
Drug: Daily steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily steroids (DS)
Study: 27897989
Drug: Sleep-low strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-low strategy (SL), CHO intake: 6 g·kg‐1·day‐1
Study: 19485591
Drug: One-session exposure
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session exposure treatment
Study: 18005932
Drug: Five-session exposure
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-session exposure treatment
Study: 15732265
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 44 mcg once weekly
Study: 15732265
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a 22 mcg once weekly
Study: 15732265
Drug: Placebo/22 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/22 mcg
Study: 15732265
Drug: Placebo/44 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/44 mcg
Study: 12958848
Drug: Donepezil capsule
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil capsule (5 mg)
Study: 12958848
Drug: Donepezil tablet
Normalized name: donepezil Oral Tablet
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil tablet (5 mg)
Study: 12958848
Drug: Donepezil capsule
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil capsule
Study: 10778658
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release formulation A (Tegretol CR, local)
Study: 10778658
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release formulation B (Tegretol CR, Basel)
Study: 10778658
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation (Tegretol)
Study: 1428134
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Vitamin K intramuscular (Menadione sodium disulphite) at birth
Study: 1428134
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Vitamin K intramuscular
Study: 1428134
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Vitamin K orally
Study: 3883857
Drug: Nebulized terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized terbutaline 1 mg in 2 mL normal saline
Study: 3883857
Drug: Subcutaneous epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous epinephrine 0.01 mg/kg (0.3 mg maximum)
Study: 28580884
Drug: MI-CBT (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI-CBT (Motivational Interviewing integrated with Cognitive-Behavioral Therapy)
Study: 30140707
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of blood glucose (BG) < 3.9 mmol/L
Study: 30140707
Drug: Area under
Approvals — FDA: no, EMA: no, PMDA: no
Description: Area under the curve for BG > 7.8 mmol/L
Study: 20370945
Drug: Lactulose in
Normalized name: Product containing lactulose in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose in liquid (L-L)
Study: 20370945
Drug: Solid lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solid lactulose (L-S)
Study: 14583173
Drug: Hypoglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic clamp (approximately 50 mg/dl)
Study: 14583173
Drug: Euglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic clamp (approximately 90 mg/dl)
Study: 10572207
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 mg via Aerolizer
Study: 10572207
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 mg via Turbuhaler
Study: 8949363
Drug: L-arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (30 g within 60 min)
Study: 8501156
Drug: Bombesin (BBS)
Normalized name: Dream Pure BB
DrugBank: Bombesin (DB11724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bombesin (BBS) infusion
Study: 8501156
Drug: Loxiglumide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide treatment alone
Study: 3123598
Drug: Deprenyl 5
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 5 mg BID
Study: 29604160
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg/d for 6 weeks
Study: 26121892
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine (5 mg/kg in 2 cc/kg apple juice)
Study: 26121892
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 cc/kg apple juice)
Study: 20209968
Drug: Xianling Gubao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xianling Gubao capsules
Study: 7925516
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg quinapril plus 12.5 mg HCTZ)
Study: 7925516
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 10 mg quinapril
Study: 7925516
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 12.5 mg HCTZ
Study: 2509737
Drug: Tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-type plasminogen activator at a dose of 0.05 mg/kg/hr (n = 4)
Study: 2509737
Drug: Tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-type plasminogen activator at a dose of 0.025 mg/kg/hr (n = 4)
Study: 2509737
Drug: Tissue-type plasminogen
Normalized name: Tissue-type plasminogen activator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue-type plasminogen activator (both doses)
Study: 17950970
Drug: Fluoxetine (10-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10-60 mg/d)
Study: 17950970
Drug: Sertraline (25-350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-350 mg/d)
Study: 16029334
Drug: Calcipotriol scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol scalp solution 50 microg mL(‐1) applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Study: 16029334
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 4 days prior to chemotherapy and continued for 14 days during each treatment cycle.
Study: 16029334
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results of treatment groups (calcipotriol and vehicle).
Study: 10589631
Drug: Ropivacaine 2
Normalized name: fentanyl-ropivacaine 2 mcg/mL-0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 2 mg/mL
Study: 10656057
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g gamma‐CD (test)
Study: 10656057
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g maltodextrin (placebo)
Study: 2192462
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections of growth hormone (0.3 mg/kg weekly)
Study: 2192462
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly injections of growth hormone (0.3 mg/kg weekly)
Study: 2192462
Drug: Once a
Normalized name: Once A Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a week injections of growth hormone (0.3 mg/kg weekly)
Study: 2192462
Drug: Daily injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injections of growth hormone (after switching from once or three times a week)
Study: 24613523
Drug: BioThrax® (anthrax
Approvals — FDA: no, EMA: no, PMDA: no
Description: BioThrax® (anthrax vaccine adsorbed) administered subcutaneously (SC) in a three-dose regimen (0, 2, and 4 weeks)
Study: 27178435
Drug: Bitopertin 30
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 30 mg
Study: 22980315
Drug: Bitopertin 175
Normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin 175 mg
Study: 15226466
Drug: Isoflavones from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones from red clover-derived dietary supplement (43.5 mg/d)
Study: 9523247
Drug: Low-level exposure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level exposure (MA + PGA < or = 159 mg/g creatinine)
Study: 9523247
Drug: High-level exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level exposure (MA + PGA > 159 mg/g creatinine)
Study: 8595636
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension 30 mg/kg per day in two divided doses (n = 235)
Study: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate suspension 40 mg/kg per day in three divided doses (n = 242)
Study: 8595636
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension (bacteriologically assessable patients)
Study: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate suspension (bacteriologically assessable patients)
Study: 8595636
Drug: Amoxicillin/clavulanate suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate suspension
Study: 24730013
Drug: BIS not
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS not visible (BIS hidden, monitoring based on clinical signs and expiratory fraction of halogenated anesthetic agents)
Study: 7811176
Drug: Metaproterenol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (80 mg/day)
Study: 2349369
Drug: Caffeine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (single dose equivalent to two to four cups of coffee)
Study: 7273596
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg brotizolam
Study: 7273596
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg brotizolam
Study: 7273596
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg flurazepam
Study: 31067587
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy by PTs with varying experience (2 to 21 years)
Study: 17614893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of didactic guidelines and netiquette advice
Study: 11351930
Drug: Intramuscular buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg)
Study: 11351930
Drug: Intramuscular hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hydromorphone (10 mg) and naloxone (0.25 mg)
Study: 11351930
Drug: Intramuscular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular buprenorphine alone (8 mg)
Study: 11351930
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine alone (8 mg)
Study: 9135734
Drug: pCMV‐CFTR:2.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: pCMV‐CFTR:2.4 mg DOTAP (400 micrograms)